AIDS Research and Human Retroviruses
Papers 7,571
1 page of 758 pages (7,571 results)
#1Parya Saberi (UCSF: University of California, San Francisco)H-Index: 17
#2Chadwick K. Campbell (UCSF: University of California, San Francisco)H-Index: 7
Last. Karine Dubé (UNC: University of North Carolina at Chapel Hill)H-Index: 16
view all 6 authors...
#1Robert J. Schieffer (NU: Northwestern University)H-Index: 2
#2Ewa Bryndza Tfaily (NU: Northwestern University)H-Index: 2
Last. Thomas J. Hope (NU: Northwestern University)H-Index: 73
view all 9 authors...
Long-acting delivery modalities of HIV pre-exposure prophylaxis (PrEP), such as subdermal implants, are in development. To facilitate end-user uptake and sustained use, it is critical to understand potential consumers' and physician prescribers' preferences about, interest in, and relative importance of different implant features. The ordered identification of these key attributes allows implant developers to incorporate this feedback into product design, which theoretically improves acceptabili...
#1Ni Sun-Suslow (UCSD: University of California, San Diego)H-Index: 3
#2Emily Balon (UCMC: University of Cincinnati Medical Center)
Last. David J. Moore (UCSD: University of California, San Diego)H-Index: 46
view all 8 authors...
Older people with HIV (PWH) experience heightened risk for the acquisition of cumulative, multisystem decline, i.e., frailty syndrome. Frailty relates to poorer sleep quality in the general older adult population; however, this association has yet to be explored among PWH. A cross-sectional analysis of 285 PWH ≥50 years old (mean age 60.5 ± 7.0) examined the relationship between frailty (Fried frailty phenotype) and self-reported sleep quality (Pittsburgh Sleep Quality Index; PSQI). Three separa...
#1Lauren Jennings (UCT: University of Cape Town)
#2Tracy Kellermann (SU: Stellenbosch University)
Last. Monica Gandhi (UCSF: University of California, San Francisco)H-Index: 48
view all 10 authors...
Introduction null The high cost of viral load (VL) testing limits its use for antiretroviral treatment (ART) adherence support. A low-cost lateral flow urine tenofovir (TFV) rapid assay predicts PrEP breakthroughs but has not yet been investigated in HIV treatment. We therefore evaluated its utility in a pilot cross-sectional study of TFV-containing ART recipients at increased risk of virologic failure. null Methods null Participants who had a treatment interruption ≥30 days or had ≥1 episode of...
#1Shigeru Kusagawa (NIH: National Institutes of Health)H-Index: 17
#2Masashi Tatsumi (NIH: National Institutes of Health)H-Index: 16
Last. Ai Kawana-Tachikawa (NIH: National Institutes of Health)H-Index: 16
view all 7 authors...
HIV-1 subtype/circulating recombinant form (CRF) distribution of HIV-1-positive specimens for evaluating HIV in vitro diagnostics (IVDs) were examined and compared with the HIV-1 epidemic in Japan. The nucleotide sequences of the gag-pol region of 173 plasma specimens (84, provided in 2007 and 89 in 2013-2015) were determined. HIV-1 subtype/CRF classification was performed based on the phylogenetic analyses of the sequences. The subtype/CRF distribution resulting in this study was similar to tha...
#1Audrey Bouchard (University of Montreal)
#2François Bourdeau (University of Montreal)
Last. Rachel Therrien (University of Montreal)
view all 9 authors...
Background: Despite availability of effective antiretroviral therapy (ART) many HIV patients still have a detectable viral load (VL). Predictive factors of detectable VL are not well documented. Th...
#1Fatima Laher (Wits: University of the Witwatersrand)H-Index: 20
Last. Bargavi Thyagarajan (IAS: International AIDS Society)
view all 27 authors...
The HIV Research for Prevention (HIVR4P) conference catalyzes knowledge-sharing on biomedical HIV prevention interventions such as HIV vaccines, antibody infusions, pre-exposure prophylaxis (PrEP) and microbicides in totality - from the molecular details and delivery formulations to the behavioral, social and structural underpinnings. HIVR4P // Virtual was held over the course of two weeks on 27-28 January and 3-4 February 2021 as the COVID-19 pandemic continued to inflict unprecedented harm glo...
#1Amanda Madyadi (College of Health Sciences, Bahrain)
#2Milcah Dhoro (College of Health Sciences, Bahrain)H-Index: 5
Last. Justen Manasa (UKZN : University of KwaZulu-Natal)H-Index: 12
view all 8 authors...
BACKGROUND Previously used as part of salvage therapy, integrase strand transfer inhibitors (INSTIs) have become part of the preferred antiretroviral therapy (ART) first-line regimen in most low-to-middle income countries. With the extensive use of dolutegravir in first-line ART, drug resistance mutations to INSTIs are inevitable. Therefore, active monitoring and surveillance of INSTI drug resistance is required. The aim of this study was to evaluate the genetic diversity of the integrase gene a...
#1Marie-Josée Brouillette (MUHC: McGill University Health Centre)H-Index: 11
#2Lisa Koski (MUHC: McGill University Health Centre)H-Index: 25
Last. Nancy E. Mayo (MUHC: McGill University Health Centre)H-Index: 65
view all 6 authors...
Background Older adults living with HIV may be at increased risk of experiencing distress during the COVID-19 pandemic. Methods We took advantage of a cohort study in older adults living with HIV in Canada (+BHN) to study the psychological impact of the first wave of the COVID-19 pandemic. A longitudinal study was conducted in which participants in the +BHN study who had access to the internet and agreed to be contacted were queried on symptoms of psychological distress and its predictors each w...
#1Jackson Wallner (Seattle Children's Research Institute)H-Index: 1
#2Ingrid A. Beck (Seattle Children's Research Institute)H-Index: 18
Last. Lisa M. FrenkelH-Index: 50
view all 9 authors...
Objective null The nucleoside reverse transcriptase inhibitor abacavir is used commonly to treat young children with HIV infection and is a component of the fixed-dose-combination Triumeq®. Abacavir can trigger a severe hypersensitivity reaction in people who are homozygous or heterozygous for HLA-B*57:01. Testing for HLA-B*57:01 prior to abacavir initiation is standard-of-care in high-resource settings, but current tests are costly or difficult to access in resource-limited settings. To address...
Top fields of study
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.